TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1‐Mediated Arachidonic Acid Metabolism
Advanced Science · 2025-02 · 12 (8)
DOI: 10.1002/advs.202413674 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 30.12.2024. Verfasst von Xiaona Fan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, P. R. China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Deoxycytidine, Drug Resistance, Neoplasm, Arachidonic Acid. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key R&D Project of Heilongjiang Province, Natural Science Funding of Heilongjiang.
Abstract (Originalsprache)
Pancreatic cancer (PC) progresses rapidly, and gemcitabine‐based chemotherapy has brought only limited efficacy. Identifying key drivers and therapeutic targets holds significant clinical value. In this study, through comprehensive analysis of multiple PC databases, this work identifies TRIM21 as a promising driver mediator. This work further performs loss‐ and gain‐of‐function assays for TRIM21, revealing that TRIM21 knockout inhibits tumor proliferation and gemcitabine resistance both in vitro and vivo. Lipidomics reveal that silencing TRIM21 reduce the arachidonic acid production, and inhibit ferroptosis. Mechanically, through proteomics, ubiquitomics, and liquid chromatography‐tandem mass spectrometry analysis, the key metabolic enzyme of arachidonic acid ‐EPHX1 is identified as a downstream substrate of TRIM21. TRIM21 interacts with EPHX1 through its SPRY domain and promotes ubiquitin‐mediated degradation of EPHX1 via K33‐ and K48‐linked ubiquitination at the K105 site. Given the targeting potential, this work screens Bezafibrate to block the interaction between TRIM21 and EPHX1 and validates its sensitizing effect. In summary, TRIM21 promotes tumour growth and gemcitabine resistance in PC by inhibiting EPHX1‐mediated arachidonic acid metabolism. This provides a novel and promising target for clinical treatment of PC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, P. R. China.
- Key Laboratory of Tumor Immunology in Heilongjiang, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
- Department of Orthopedic Surgery, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
- Department of Anatomy, Harbin Medical University, Harbin, 150081, China.
ORCID-Profile: Zhiwei Li
Förderung
- National Natural Science Foundation of China
- Key R&D Project of Heilongjiang Province
- Natural Science Funding of Heilongjiang
- Haiyan Research Fund of Harbin Medical University Cancer Hospital
Zitieren
APA
Fan, X., Dai, Y., Mo, C., Li, H., Luan, X., Wang, B., Yang, J., Jiao, G., Lu, X., Chen, Z., Liao, Y., Qu, L., Yang, H., Lou, C., Liu, C., & Li, Z. (2025). TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1‐Mediated Arachidonic Acid Metabolism. Advanced Science, 12(8). https://doi.org/10.1002/advs.202413674
Vancouver
Fan X, Dai Y, Mo C, Li H, Luan X, Wang B, et al. TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1‐Mediated Arachidonic Acid Metabolism. Advanced Science. 2025;12(8). doi:10.1002/advs.202413674
BibTeX
@article{Fan2025,
author = {Fan, Xiaona and Dai, Yisheng and Mo, Chuanfeng and Li, Hengzhen and Luan, Xindi and Wang, Bojun and Yang, Jiani and Jiao, Guangtao and Lu, XiaoLin and Chen, Zhuo and Liao, Yuanyu and Qu, Ling and Yang, Huike and Lou, Changjie and Liu, Chao and Li, Zhiwei},
title = {TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1‐Mediated Arachidonic Acid Metabolism},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {8},
doi = {10.1002/advs.202413674}
}
EUVIMED